AstraZeneca Pharma India Limited, a subsidiary of AstraZeneca Plc, UK, has made a regulatory announcement regarding the proposed sale of its production site in Bengaluru. This decision forms part of the company’s ongoing strategic evaluation. The company emphasised its commitment to its workforce, stating that its primary obligation lies in safeguarding the interests of its employees amidst this transition.
Additionally, AstraZeneca Pharma India is taking steps to ensure that this change does not disrupt the supply of medicines, thereby continuing to meet patient needs effectively. Founded in 1979 and headquartered in Bengaluru, the company currently employs over 1,400 staff members across India. The company primarily focuses on researching, developing, and marketing prescription drugs, with a special emphasis on oncology, cardiovascular, renal metabolic, and respiratory therapies.